Table 3.
The most prevalent genomic alterations in pathway analysis.
| Pathway | Mutation frequency (%) |
p Value | |
|---|---|---|---|
| Early recurrence TNBCs (N = 23) | No recurrence TNBCs (N = 13) | ||
| PI3K/mTOR | 14 (60.8%) | 4 (30.8%) | .164 |
| PTEN | 8 (34.7%) | 2 (15.4%) | |
| PIK3CA | 6 (26.0%) | 2 (15.4%) | |
| PIK3C2B | 3 (13.0%) | 0 | |
| PIK3R1 | 1 (4.3%) | 0 | |
| STK11 | 1 (4.3%) | 0 | |
| Cell cycle | 12 (52.1%) | 2 (15.4%) | .039 |
| RB1 | 7 (30.4%) | 1 (7.7%) | |
| CCND1 | 3 (13.0%) | 0 | |
| CCNE1 | 0 | 1 (7.7%) | |
| CDK12 | 1 (4.3%) | 0 | |
| CCND2 | 1 (4.3%) | 0 | |
| CDK6 | 1 (4.3%) | 0 | |
| CDKN2B | 1 (4.3%) | 0 | |
| CDKN2A | 1 (4.3%) | 0 | |
| DNA repair | 10 (43.4%) | 3 (23.1%) | .292 |
| BRCA1 | 5 (21.7%) | 1 (7.7%) | |
| RAD21 | 2 (8.7%) | 1 (7.7%) | |
| BRCA2 | 0 | 1 (7.7%) | |
| PALB2 | 1 (4.3%) | 0 | |
| MSH1 | 1 (4.3%) | 0 | |
| MLH1 | 1 (4.3%) | 0 | |
| BRIP1 | 1 (4.3%) | 0 | |
| BAP1 | 1 (4.3%) | 0 | |
| GFRs | 5 (21.7%) | 4 (30.8%) | .693 |
| ERBB2 | 2 (8.7%) | 0 | |
| FGFR1 | 0 | 2 (15.4%) | |
| EGFR | 1 (4.3%) | 1 (7.7%) | |
| IGF1R | 1 (4.3%) | 1 (7.7%) | |
| FGFR2 | 1 (4.3%) | 0 | |
| ROS1 | 1 (4.3%) | 1 (7.7%) | |
| ERBB4 | 0 | 1 (7.7%) | |
| KIT | 0 | 1 (7.7%) | |
| RAS/MAPK | 4 (17.3%) | 0 (0%) | NS |
| KRAS | 2 (8.7%) | 0 | |
| NF1 | 2 (8.7%) | 0 | |